Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: Cracking the glass ceiling of early death

Blood

Volumn 129, Issue 15, 2017, Pages 2111-2119

  Muchtar, Eli ^a   Gertz, Morie A ^a   Kumar, Shaji K ^a   Lacy, Martha Q ^a   Dingli, David ^a   Buadi, Francis K ^a   Grogan, Martha ^a   Hayman, Suzanne R ^a   Kapoor, Prashant ^a   Leung, Nelson ^a   Fonder, Amie ^a   Hobbs, Miriam ^a   Hwa, Yi Lisa ^a   Gonsalves, Wilson ^a   Warsame, Rahma ^a   Kourelis, Taxiarchis V ^a   Russell, Stephen ^a   Lust, John A ^a   Lin, Yi ^a   Go, Ronald S ^a   Zeldenrust, Steven ^a   Kyle, Robert A ^a   Rajkumar, S Vincent ^a   Dispenzieri, Angela ^a   more..

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MELPHALAN; PREDNISOLONE; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AL AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; AMYLOIDOSIS; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; INDUCTION CHEMOTHERAPY; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

AGED; AMYLOIDOSIS; AUTOGRAFTS; BORTEZOMIB; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INDUCTION CHEMOTHERAPY; MALE; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 85018894692     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-11-751628     Document Type: Article

References (25)

1. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: Diagnosis and management. Clin Lymphoma Myeloma. 2005;6(3):208-219.
2. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
3. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR III, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114(24): 4957-4959.
4. Majolino I, Marceno R, Pecoraro G, et al. Highdose therapy and autologous transplantation in amyloidosis-AL. Haematologica. 1993;78(1): 68-71.
5. Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients. Blood. 2011;118(16):4346-4352.
6. Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004;103(8): 2936-2938.
7. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomibdexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
8. Palladini G, Milani P, Foli A, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: A matched case-control study on 174 patients. Leukemia. 2014;28(12):2311-2316.
9. Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid. 2003; 10(4):257-261.
10. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood. 2007;109(2):492-496.
11. Dispenzieri A, Dingli D, Kumar SK, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010;85(10):757-759.
12. Kaufman G, Witteles R, Wheeler M, et al. Daratumumab yields rapid hematologic responses in patients with heavily pretreated, relapsed AL amyloidosis. Clin Lymph Myeloma Leuk. 2016; 16(Suppl 2):S75.
13. Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128(15):1987-1989.
14. Gertz MA, Landau H, Comenzo RL, et al. First-inhuman phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10): 1097-1103.
15. Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015; 373(12):1106-1114.
16. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1): 12-18.
17. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038): 2641-2654.
18. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4):319-328.
19. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic lightchain amyloidosis. Leukemia. 2012;26(11): 2317-2325.
20. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: Patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32(10): 920-928.
21. Palladini G, Kyle RA, Larson DR, Therneau TM, Merlini G, Gertz MA. Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis. Amyloid. 2005; 12(2):120-126.
22. Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99(9):1479-1485.
23. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twiceweekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study. Blood. 2011;118(4):865-873.
24. Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33(12):1371-1378.
25. Muchtar E, Dispenzieri A, Kumar SK, et al. Interphase fluorescence in-situ hybridization (iFISH) in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category [published online ahead of print 16 December 2016]. Leukemia. doi:10.1038/leu.2016.369.